Home/Ridgeline Therapeutics/Stan Watowich, PhD

SW

Stan Watowich, PhD

Founder & CEO

Ridgeline Therapeutics

Therapeutic Areas

Metabolic Diseases Musculoskeletal Disorders Renal Disease

Ridgeline Therapeutics Pipeline

Drug	Indication	Phase
NNMT Inhibitor Program	Sarcopenia/Frailty, Type 2 Diabetes, Obesity, Muscular Dystrophies, Kidney Disease	Preclinical

Leadership Team at Ridgeline Therapeutics

Harshini Neelakantan, PhD

Exec. Director, Research & Development

Suzanne Tomlinson, PhD, MBA

Director, Finance & Operations

View full Ridgeline Therapeutics profile